secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001193125-24-062878
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Phase 3 ALS trial misses primary endpoint; may withdraw RELYVRIO
-----------------------------------------------------------------------

- PHOENIX trial: no significant difference on ALSFRS-R at Week 48 (p=0.667); secondary endpoints also missed.
- Company may voluntarily withdraw RELYVRIO/ALBRIOZA from market; will decide within 8 weeks after regulatory discussions.
- Promotion paused immediately; drug and patient support remain available for now.
- Study enrolled 664 adults; safety profile consistent, no new signals.
- Phase 3 ORION in PSP and Phase 2 HELIOS in Wolfram syndrome continue as planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524062878/0001193125-24-062878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524062878/d787565d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-062878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer